Argitalpenak (104) María José Carmena Sierra argitalpenak

2024

  1. Antagonist of Growth Hormone-Releasing Hormone Receptor MIA-690 Suppresses the Growth of Androgen-Independent Prostate Cancers

    International Journal of Molecular Sciences, Vol. 25, Núm. 20

  2. Study of the microRNA fraction in food waste and other biomasses. Assessment of its antioxidant and anti-inflammatory activity

    Journal of Functional Foods, Vol. 119

2023

  1. Amphiphilic Dendritic Hydrogels with Carbosilane Nanodomains: Preparation and Characterization as Drug Delivery Systems

    Chemistry of Materials, Vol. 35, Núm. 7, pp. 2797-2807

  2. Extraction, detection and determination of dietary microRNA: A review

    Trends in Food Science and Technology, Vol. 135, pp. 215-233

2022

  1. Tumorigenic transformation of human prostatic epithelial cell line RWPE-1 by growth hormone-releasing hormone (GHRH)

    Prostate, Vol. 82, Núm. 8, pp. 933-941

2020

  1. Búsqueda de nuevas dianas de interés farmacológico con actividad inmunomoduladora para el tratamiento de las enfermedades infecciosas

    Dianas: revista de dianas terapéuticas, Vol. 9, Núm. 2

  2. Heterofunctional ruthenium(II) carbosilane dendrons, a new class of dendritic molecules to fight against prostate cancer

    European Journal of Medicinal Chemistry, Vol. 207

  3. Stimulation of neuroendocrine differentiation in prostate cancer cells by GHRH and its blockade by GHRH antagonists

    Investigational New Drugs, Vol. 38, Núm. 3, pp. 746-754

2019

  1. Anticancer Activity of Dendriplexes against Advanced Prostate Cancer from Protumoral Peptides and Cationic Carbosilane Dendrimers

    Biomacromolecules, Vol. 20, Núm. 3, pp. 1224-1234

  2. In vitro and in vivo evaluation of first-generation carbosilane arene Ru(II)-metallodendrimers in advanced prostate cancer

    European Polymer Journal, Vol. 113, pp. 229-235

2018

  1. Growth hormone-releasing hormone receptor antagonists modify molecular machinery in the progression of prostate cancer

    Prostate, Vol. 78, Núm. 12, pp. 915-926

  2. In vitro antitumor and hypotensive activity of peptides from olive seeds

    Journal of Functional Foods, Vol. 42, pp. 177-184

2017

  1. Growth hormone-releasing hormone (GHRH) promotes metastatic phenotypes through EGFR/HER2 transactivation in prostate cancer cells

    Molecular and Cellular Endocrinology, Vol. 446, pp. 59-69

2016

  1. Anti-proliferative and pro-apoptotic effects of GHRH antagonists in prostate cancer

    Oncotarget, Vol. 7, Núm. 32, pp. 52195-52206

  2. Growth hormone-releasing hormone induced transactivation of epidermal growth factor receptor in human triple-negative breast cancer cells

    Peptides, Vol. 86, pp. 153-161

  3. Polyphenolic carbosilane dendrimers as anticancer agents against prostate cancer

    New Journal of Chemistry, Vol. 40, Núm. 12, pp. 10488-10497

  4. Transactivación de EGFR y HER2 inducida por la hormona liberadora de la hormona del crecimiento (GHRH) en cáncer de próstata avanzado

    Quintas Jornadas de Jóvenes Investigadores de la Universidad de Alcalá: Ciencias e Ingenierías

2015

  1. VIP induces NF-κB1-nuclear localisation through different signalling pathways in human tumour and non-tumour prostate cells

    Cellular Signalling, Vol. 27, Núm. 2, pp. 236-244

2014

  1. Growth hormone-releasing hormone antagonists abolish the transactivation of human epidermal growth factor receptors in advanced prostate cancer models

    Investigational New Drugs, Vol. 32, Núm. 5, pp. 871-882

  2. Signalling pathways involved in antitumoral effects of VIP in human renal cell carcinoma A498 cells: VIP induction of p53 expression

    International Journal of Biochemistry and Cell Biology, Vol. 53, pp. 295-301